• English
  • 中文繁体
  • 中文简体
Hi,
moomoo ID:NaN
Log Out
donwloadimg

Download App

Log in to access Online Inquiry
Quotes
Detailed Quotes
Company Overview
Company ProfileCompany Executives
Financial Analysis
Main CompositionKey IndicatorsFinancial Statement
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > GBT Global Blood Therapeutics > Detailed Quotes

GBT Global Blood Therapeutics

66.750
+0.180+0.27%
Close 08/12 16:00 ET
66.720
-0.03-0.04%
Post Mkt Price 08/12 16:06 ET
High
66.810
Open
66.670
Turnover
384.06M
Low
66.590
Pre Close
66.570
Volume
5.76M
Market Cap
4.50B
P/E(TTM)
Loss
52wk High
73.020
Shares
67.46M
P/E(Static)
Loss
52wk Low
21.650
Float Cap
3.51B
Bid/Ask %
-50.00%
Historical High
87.540
Shs Float
52.61M
Volume Ratio
0.40
Historical Low
12.240
Dividend TTM
--
Div Yield TTM
250
P/B
38.06
Dividend LFY
--
Div Yield LFY
374.53%
Turnover Ratio
10.94%
Amplitude
0.33%
Avg Price
66.720
Lot Size
1
Float Cap
3.51B
Bid/Ask %
-50.00%
Historical High
87.540
Shs Float
52.61M
Volume Ratio
0.40
Historical Low
12.240
Dividend TTM
--
P/B
38.06
Dividend LFY
--
Turnover Ratio
10.94%
Amplitude
0.33%
Avg Price
66.720
Lot Size
1
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast

No Data

News

Comment

News

Announcement

All

Earnings Report

Related Transactions

Changes In Ownership

Major Events

Other

Company Overview More
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
CEO： Love M.D., Ted W.
Market： NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...